These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22529801)

  • 21. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study.
    Garcovich S; Ruggeri A; D'Agostino M; Ardito F; De Simone C; Delogu G; Fadda G
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1572-6. PubMed ID: 21923840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
    Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
    Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
    Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.
    Noguera-Julian A; Calzada-Hernández J; Brinkmann F; Basu Roy R; Bilogortseva O; Buettcher M; Carvalho I; Chechenyeva V; Falcón L; Goetzinger F; Guerrero-Laleona C; Hoffmann P; Jelusic M; Niehues T; Ozere I; Shackley F; Suciliene E; Welch SB; Schölvinck EH; Ritz N; Tebruegge M
    Clin Infect Dis; 2020 Dec; 71(10):2561-2569. PubMed ID: 31796965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy.
    Shim TS
    Intest Res; 2014 Jan; 12(1):12-9. PubMed ID: 25349559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors.
    Gilbert KE; Manalo IF; Wu JJ
    Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.
    Cantini F; Nannini C; Niccoli L; Petrone L; Ippolito G; Goletti D
    Mediators Inflamm; 2017; 2017():8909834. PubMed ID: 28659665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial Quantiferon-TB Gold test results in 279 patients with psoriasis receiving biologic therapy.
    Akdogan N; Dogan S; Gulseren D; Yalici-Armagan B; Ersoy-Evans S; Elcin G; Karaduman A; Atakan N
    Dermatol Ther; 2021 Jan; 34(1):e14699. PubMed ID: 33368959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
    Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
    J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.
    Hsia EC; Cush JJ; Matteson EL; Beutler A; Doyle MK; Hsu B; Xu S; Rahman MU
    Arthritis Care Res (Hoboken); 2013 Feb; 65(2):309-13. PubMed ID: 22782640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.
    Oh JH; Ham SP; Park HJ
    Ann Dermatol; 2021 Feb; 33(1):77-81. PubMed ID: 33911816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer.
    Bordignon V; Bultrini S; Prignano G; Sperduti I; Piperno G; Bonifati C; Filippetti M; Toma L; Latini A; Di Cecio M; Giuliani A; Vocaturo A; Trento E; D' Agosto G; Francesconi F; Cataldo A; Vento A; Cilenti V; Berardesca E; Ameglio F; Cordiali Fei P; Ensoli F
    J Biol Regul Homeost Agents; 2011; 25(2):213-20. PubMed ID: 21880210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy.
    Vaughn BP; Doherty GA; Gautam S; Moss AC; Cheifetz AS
    Inflamm Bowel Dis; 2012 Jun; 18(6):1057-63. PubMed ID: 21953829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
    Pettipher C; Benitha R
    Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue.
    Marino S; Sud D; Plessner H; Lin PL; Chan J; Flynn JL; Kirschner DE
    PLoS Comput Biol; 2007 Oct; 3(10):1909-24. PubMed ID: 17953477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.